12 Oct The MIGHT Trial
The main purpose of this study/trial is to test whether patients with HMGCR myopathy can be safely and effectively treated with IVIG as their only medication for this condition.
Participant Eligibility
Potential subjects must meet the following:
– Have a positive Anti-HMGCR antibody lab result within 12 months prior to enrollment
-Age 18 and older
-Demonstrate proximal muscle weakness
-Serum creatinine kinase (CK) more than 5 times the upper limit of normal
Contact
Leslie Lazar Thorn
(206) 744-9143
Additional Study Details
Full Study Title
Monotherapy IVIG for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment
Study ID: Study00009143
ClinicalTrials.gov Link: NCT04450654
Start Date: 10/01/2020
End Date: 10/01/2023
Investigator(s)
James Andrews, MD
Accepts Healthy Volunteers?
No
Study Site(s)
University of Washington (Montlake)
1959 NE Pacific St
Seattle, Washington 98195
